INCY — Incyte Corporation

Summary of Incyte Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $1.27 billion, up 21% year-over-year.
• Net Sales: $1.1 billion, reflecting a 20% increase from the previous year.
• Jakafi Sales: $758 million, a 7% increase year-over-year.
• Core Business (ex-Jakafi) Sales: Up 63% year-over-year, totaling $343 million.
• GAAP R&D Expenses: $516 million, an 18% increase driven by late-stage development investments.
• GAAP SG&A Expenses: $328 million, up 1% year-over-year.
• Operating Leverage: Continued improvement with operating expenses growing at a lower rate than revenues.

2. Strategic Updates and Business Highlights:

• Incyte is transitioning from reliance on Jakafi to a diversified portfolio across hematology, oncology, and immunology.
• Key regulatory milestones include FDA acceptance of the application for povorcitinib for hidradenitis suppurativa (HS) and positive results from Phase III studies in vitiligo.
• The company is preparing for multiple product launches, including Jakafi XR and Opzelura for moderate atopic dermatitis in Europe.
• Leadership changes were announced, including the appointment of Suky Upadhyay as CFO and Pablo Cagnoni as President and Global Head of R&D.

3. Forward Guidance and Outlook:

• Full-year 2026 net sales guidance is set at $4.77 billion to $4.94 billion, indicating a 10% to 13% increase from the prior year.
• Jakafi is expected to generate $3.22 billion to $3.27 billion in sales, while Opzelura is projected to bring in $750 million to $790 million.
• The core business (excluding Jakafi) has the potential to reach $3 billion to $4 billion by 2030.

4. Bad News, Challenges, or Points of Concern:

• Despite strong overall sales growth, Jakafi's growth rate has slowed, indicating potential market saturation.
• Competitive pressures in the dermatology space, particularly for Opzelura, as the market shifts towards non-steroidal treatments.
• The company faces the challenge of successfully launching multiple new products while maintaining operational efficiency and managing costs.

5. Notable Q&A Insights:

• Management expressed confidence in the dual marketing strategy for povorcitinib and Opzelura in the vitiligo market, highlighting the potential for both products to address different patient segments.
• The FDA's flexibility regarding endpoints in clinical trials for 989 (mutant CALR antibody) is seen as a positive sign for future regulatory discussions.
• Concerns were raised about the potential for dose escalation in pivotal trials, particularly in the context of patient variability and efficacy in the mutant CALR population.
• The company remains optimistic about the uptake of povorcitinib, especially in both pre- and post-biologic treatment settings for HS, with peak sales estimates ranging from $500 million to $1 billion.

Overall, Incyte reported a strong start to 2026, with significant growth in revenue and strategic advancements in its pipeline, while also navigating challenges related to competition and market dynamics.